1. Home
  2. TDS vs CRSP Comparison

TDS vs CRSP Comparison

Compare TDS & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telephone and Data Systems Inc.

TDS

Telephone and Data Systems Inc.

HOLD

Current Price

$44.09

Market Cap

5.2B

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$54.25

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TDS
CRSP
Founded
1968
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
5.1B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
TDS
CRSP
Price
$44.09
$54.25
Analyst Decision
Strong Buy
Buy
Analyst Count
3
19
Target Price
$51.67
$71.50
AVG Volume (30 Days)
1.0M
1.6M
Earning Date
02-20-2026
02-10-2026
Dividend Yield
0.36%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,859,865,000.00
$38,337,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,299.68
P/E Ratio
N/A
N/A
Revenue Growth
110.05
N/A
52 Week Low
$31.07
$30.04
52 Week High
$45.02
$78.48

Technical Indicators

Market Signals
Indicator
TDS
CRSP
Relative Strength Index (RSI) 65.51 47.10
Support Level $43.27 $51.00
Resistance Level $45.02 $57.99
Average True Range (ATR) 1.29 2.63
MACD 0.25 -0.18
Stochastic Oscillator 83.22 33.50

Price Performance

Historical Comparison
TDS
CRSP

About TDS Telephone and Data Systems Inc.

Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: